Aztiq Pharma Partners Invests $100M to Buy 17% Stake in Alvogen US
June 30, 2021
Aztiq Pharma Partners completed a $100 million financing to acquire a newly issued 17% equity stake in Alvogen US at a pre-money valuation of $350 million, with Morgan Stanley leading the financing. The funding will support increased R&D investment and expansion of branded sales channels in the U.S., and following the transaction Aztiq holds a combined direct and indirect stake of approximately 40% in Alvogen US.
- Buyers
- Aztiq Pharma Partners
- Targets
- Alvogen US
- Sellers
- Alvogen Lux Holdings
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Aztiq and Innobic Consortium Acquires Alvogen Emerging Markets Holdings for $500M
May 10, 2022
Pharmaceuticals
Aztiq Pharma Partners (led by Róbert Wessman) and Innobic (Asia) Company Limited, through Aztiq II HoldCo, completed a $500 million acquisition of 100% of Alvogen Emerging Markets Holdings Limited (AEMH). The deal makes the consortium the leading shareholder in Lotus Pharmaceuticals and the owner of Alvogen Malta Holding Ltd. (the shareholder of Adalvo), positioning the group to expand pharmaceutical capabilities and commercial reach—particularly across ASEAN markets.
-
GHO Capital and Partners Group Invest in Sterling Pharma Solutions
May 25, 2023
Pharmaceuticals
GHO Capital (majority owner) and Partners Group have completed an investment into GHO portfolio company Sterling Pharma Solutions, with Partners Group acquiring a significant minority stake. The transaction is supported by a consortium led by funds managed by AlpInvest Partners and Pantheon and will fund Sterling's expansion of production capacity, capability build-out and further strategic acquisitions across the UK, Europe and the US.
-
AstraZeneca (Alexion) Acquires Amolyt Pharma for Up to $1.05 Billion
March 14, 2024
Biotechnology
Amolyt Pharma, a clinical-stage biotech focused on rare endocrine diseases, entered into a definitive agreement to be acquired by AstraZeneca’s Rare Disease business (Alexion) for $800 million upfront plus up to $250 million in regulatory milestone contingent payments. The total deal value is up to $1.05 billion and is expected to close by the end of Q3 2024, subject to customary closing conditions and regulatory clearances.
-
GHO Capital Acquires Majority Stake in Sterling Pharma Solutions
February 28, 2019
Pharmaceuticals
GHO Capital has acquired a majority stake in Sterling Pharma Solutions alongside management. The investment will support Sterling's international expansion and accelerate growth of its specialist API development and GMP manufacturing capabilities from its UK base in Newcastle upon Tyne.
-
Fulgent Genetics Acquires Fulgent Pharma
November 7, 2022
Biotechnology
Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.
-
Equistone Partners Europe Acquires Majority Stake in Omnicare
August 14, 2019
Pharmaceuticals
Equistone Partners Europe has agreed to acquire a majority stake in Omnicare, a German pharmaceutical wholesaler specializing in distribution of finished medicines to compounding pharmacies for patient-specific oncology treatments. The seller is a consortium of shareholders that will retain a stake; Omnicare’s management, led by Oliver Tamimi, will remain in place and the deal (terms undisclosed) is expected to close in Q4 2019.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.